Intervacc has signed a Letter of Intent and an agreement on first mile stones with 3P Biopharmaceuticals in Pamplona, Spain, for contract manufacturing of Strangvac®, Intervacc´s recombinant vaccine against strangles. The collaboration between the Companies covers transfer of the manufacturing technology, production of validation batches and long term future commercial manufacturing.
“We are very pleased about this agreement, this is a significant step forward for Intervacc, which thereby enters into a new commercial production phase after successful completion of clinical trials and safety studies of Strangvac®” says Jan-Ingmar Flock, CEO of Intervacc.
3P Biopharmaceuticals was recognised by Intervacc as one of only few Contract Manufacturing Organisations with a well documented technical skill, regulatory experience, facilities and track record on manufacturing of recombinant proteins as vaccine components.
Strangvac® is Intervacc´s vaccine against strangles, caused by Streptococcus equi in the horse. Strangles is a very contagious and severe infection leading to significant suffering and economic loss for the global horse industry. There is a huge need for a safe and efficacious vaccine against strangles as evidenced by all current reported outbreaks from the markets.
Intervacc AB (publ) is a company within the Biotechnology sector. The Company´s main area is to develop modern sub-unit vaccines against economically important bacterial infections, mainly within animal health. The company´s vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the company´s research and development work.
About 3P Biopharmaceuticals3P Biopharmaceuticals is a leading European CDMO specialized in the process development and GMP manufacturing of biologics and cell therapy products. 3P offers its customers solutions at all stages of bio drug development: from initial research, preclinical and clinical phases to commercial phases. Its extensive experience in projects covering all stages of the process development and manufacturing in three different expression systems (mammalian, bacterial and yeasts), its flexibility and adaptation with its innovative technology and its vast human capital have made it a reference for the European market. Visit http://www.3pbio.com/ for more information about 3P Biopharmaceuticals.
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
Un equipo de investigadores de la Universidad Juli...
En nuestro post hablamos sobre este interesante tipo de célula del...
Regenera Activa Worldwide and Rigenera HBW, biotech firms specializing...
